AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 18.2813
- Book/Share 14.4548
- PB 10.6187
- Debt/Equity 0.7343
- CurrentRatio 0.8629
- ROIC 0.1089
- MktCap 475063261200.0
- FreeCF/Share 3.0844
- PFCF 49.6836
- PE 57.0469
- Debt/Assets 0.2921
- DivYield 0.0201
- ROE 0.1991
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
Are these the UK's top income stocks? One leading bank thinks so
Published: July 02, 2025 by: Proactive Investors
Sentiment: Neutral
Reliable income stocks are a staple of a balanced portfolio. But according to research from UBS, the UK has only a handful that warrant close attention.
Read More
AstraZeneca shares pop on news CEO wants to move base to US
Published: July 01, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) shares spiked higher on Tuesday afternoon on reports that the boss of the UK pharmaceutical giant wants to move the company to the US. CEO Pascal Soriot wants to the FTSE 100's largest company to leave the UK due to his frustration with restrictions on medicines and pricing under the NHS, according to a report in The Times.
Read More
AstraZeneca CEO eyes US market listing, The Times reports
Published: July 01, 2025 by: Reuters
Sentiment: Positive
AstraZeneca chief executive Pascal Soriot is considering moving the company's stock market listing to the United States, The Times reported on Tuesday, citing multiple sources.
Read More
AstraZeneca: Navigating Challenges Across Geographies Well
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Negative
AstraZeneca's price performance YTD exceeds the healthcare sector and broader markets, indicating investors are assuaged regarding concerns across geographies. The company has offered greater clarity on why its under investigation in China, and so far there's reason to believe matters are under control. US tariffs are unlikely to affect its financials significantly in 2025 either, with the company assuring that only a minority of treatments are imported into the market.
Read More
Is Astrazeneca (AZN) a Buy as Wall Street Analysts Look Optimistic?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.
Read More
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
AstraZeneca and GSK fall after Trump renews pharma tariff threat
Published: June 18, 2025 by: Proactive Investors
Sentiment: Negative
Shares in AstraZeneca PLC (LSE:AZN), the largest company on the FTSE 100 index, and fellow blue chip GSK PLC (LSE:GSK, NYSE:GSK) were down 1.4% and 1.9% respectively on renewed worries about US drug tariffs. The pharmaceutical pair were a large drag on the London index after US President Donald Trump said tariffs on imported drugs could be imposed “very soon”, echoing comments from two months ago.
Read More
Is Trump targeting the NHS in trade negotiations? This reports says it is
Published: June 16, 2025 by: Proactive Investors
Sentiment: Negative
Britain could face higher drug costs as part of a deal to stave off future tariffs from Donald Trump, according to a report in the Daily Telegraph. Documents released after a recent trade agreement show the NHS is expected to review its approach to drug pricing in response to US demands.
Read More
Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes
Published: June 12, 2025 by: Proactive Investors
Sentiment: Positive
UBS has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, offering potential upside of just over 30% from the current share price of 10,907p. The focus is on two high-profile drug candidates with contrasting outlooks.
Read More
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
Astrazeneca (AZN) closed the most recent trading day at $71.93, moving -1.24% from the previous trading session.
Read More
AstraZeneca CEO Pascal Soriot on breast cancer drug trial
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."
Read More
AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, and more.
Read More
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Published: June 02, 2025 by: Investors Business Daily
Sentiment: Neutral
Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.
Read More
Danaher Partners With AstraZeneca to Support Precision Medicine
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Read More
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
Read More
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
Read More
Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and AstraZeneca announce licensing agreement to develop AI-powered screening algorithms for early disease detection.
Read More
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
Read More
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical response in the first eight patients evaluated Results equate to an objective response rate (CRs and PRs) of 63% Data from an earlier cutoff date in February are included in an abstract published today by the European Hematology Association (EHA) 2025 conference LUND, SE / ACCESS Newswire / May 14, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory …
Read More
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone. The trial was not statistically pow.
Read More
AstraZeneca's Imfinzi delays bladder cancer return in high-risk patients
Published: May 09, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) has reported encouraging results from a late-stage trial of its cancer immunotherapy Imfinzi, which significantly extended the time patients with early-stage bladder cancer lived without their disease coming back or getting worse. The data, released Friday, come from the company's phase III POTOMAC trial and mark a potential breakthrough for patients with high-risk non-muscle-invasive bladder cancer, a form of the disease that accounts for the majority of bladder cancer diagnoses and has a stubborn tendency to return.
Read More
AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief
Published: May 07, 2025 by: Proactive Investors
Sentiment: Negative
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) on the back of an appointment by Donald Trump and his health secretary Robert F Kennedy Jnr of a key position at the US drug regulator. Vinay Prasad, a vaccine sceptic like Kennedy, has been made head of the US Food and Drug Administration's Center for Biologics Evaluation and Research.
Read More
AZN or ARGX: Which Is the Better Value Stock Right Now?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
AstraZeneca has plenty coming down the pipeline to appease the bears
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS believes underplays the company's longer-term potential. The bank retains its 'buy' rating with a price target of 14,200p, offering more than 30% upside from the current share price of around 10,600p.
Read More
AstraZeneca has built resilient supply chains in U.S., China: CEO
Published: April 29, 2025 by: CNBC International TV
Sentiment: Positive
AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300